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Abstract
Aim Atrial fibrillation (AF) is a common cardiac
arrhythmia, and is associated with worsening quality of
life and complications such as stroke. Previous work
showed that 8% of patients develop new-onset AF fol-
lowing colonic resection and highlighted factors that
might predict the development of postoperative AF.
The development of a new arrhythmia may have a nega-
tive effect on longer-term quality of life as well as cancer
survivorship. The aim of this study is to accurately
quantify the incidence of AF following colorectal cancer
surgery and to validate a model to predict its develop-
ment.
Method The Atrial Fibrillation After Resection (AFAR)
study will recruit 720 patients aged 65 or over under-
going resection of colorectal cancer with curative intent.
The primary outcome is development of AF within
90 days of surgery. Assessment of cardiac rhythm will
be performed using 24-h Holter monitors at baseline,
30 and 90 days after surgery. An electrocardiogram
(ECG) will be performed on the day of discharge. Base-
line descriptors including model variables and quality of
life will be recorded using EQ-5D-5L. The occurrence
of complications and other key surgical outcomes will
be recorded. An additional blood test for N-terminal
pro B-type natriuretic peptide (NT-proBNP) will be
performed prior to surgery. Statistical analysis will vali-
date a previously derived model and will test the incre-
mental value of added variables such as NT-proBNP.
Finally, an exploratory analysis will assess whether
changes in ECG measures between baseline and postop-
erative ECG can predict subsequent new-onset AF.
Conclusion This study will provide data that may allow
us to stratify the risk of developing AF following col-
orectal cancer surgery. This may inform screening or
prophylactic approaches.
Keywords Colorectal cancer, atrial fibrillation, stratifi-
cation
Introduction
Atrial fibrillation (AF) is a common condition character-
ized by chaotic electrical cardiac activity resulting in loss
of atrial contraction. This affects filling of the ventricles
and can impair cardiac function, leading to symptoms
such as shortness of breath and dizziness. Blood stasis
allows clots to form within the atria, increasing the risk
of systemic embolism and stroke. It has an estimated
prevalence of 3.7–4.2% in those aged 60–70 years and
of 10–17% in those aged 80 years or older [1].
Following abdominal surgery, AF occurs in approxi-
mately 12–15% of patients [2]. This can be associated
with a complication of surgery, such as an ‘anastomotic
leakage’ or pelvic collection, or with other cardiovascu-
lar or respiratory complications. However, some patients
develop AF without an obvious underlying complica-
tion. Clinically significant new-onset AF is associated
with a longer hospital length of stay [3], and increased
risk of stroke within 30 days (OR 3.51, 95% CI 1.45–
8.52) [4]. Perioperative AF is also associated with an
increased risk of stroke, myocardial infarction and death
at 1 year [1]. A large number of colorectal cancer resec-
tions are carried out in those over 65 years of age [5].
As the surgical population ages this number will inevita-
bly increase, with a commensurate elevation in AF dis-
ease burden.
AF can be paroxysmal (intermittent) or persistent.
This presents a challenge when attempting to secure a
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diagnosis. Investigation with a single electrocardiogram
(ECG) may capture just a few seconds of cardiac
rhythm when AF is not present, resulting in a patient
being falsely reassured. Ambulatory monitoring, such
as with a Holter monitor, assesses cardiac rhythm over
a longer period, typically 24 h, providing greater
opportunity to detect paroxysmal AF. Many patients
with AF are asymptomatic, and up to 50% of cases
may be undiagnosed [6]. Current evidence suggests
that asymptomatic AF may still carry significant risk
for mortality and morbidity [7]. Paroxysmal AF often
goes undetected, and therefore untreated, unlike per-
sistent AF.
The majority of evidence regarding postoperative AF
is related to cardiac and thoracic surgery. This includes
a number of trials evaluating prophylactic beta-blockers
and amiodarone for the prevention and treatment of AF
[4,8]. A recent Cochrane review has shown that the
benefit of prophylactic beta-blockade in noncardiac sur-
gery is doubtful at best [2]. The aetiology of AF after
cardiac surgery and abdominal visceral surgery differs,
with the former being directly related to surgical manip-
ulation of the heart and pulmonary vessels. The causes
of new AF after noncardiac surgery are more complex
and are related to the response to the systemic insult of
surgery and factors that render the myocardium intrinsi-
cally vulnerable. Proposed mechanisms for the develop-
ment of postoperative AF are multifactorial. The event
of surgery, or complications such as anastomotic leak-
age, can cause systemic inflammation, which sensitizes
the pacemaker cells. This may be augmented by
increased sympathetic tone in response to surgery as
well as to pain. There may be changes in myocardial
electrical function due to altered oxygen delivery, intra-
operative variation in blood pressure and fluid adminis-
tration. These might cause AF alone, or may have
effects augmented in a susceptible atrial substrate stimu-
lated by a number of factors to cause arrhythmia
[9,10]. This information is summarized in Fig. 1.
Our previous work investigated the incidence of new
AF following gastrointestinal surgery using seven
patient features available from routinely collected hospi-
tal data [3] and summarized in Table 1. That study
found that 6.5% of patients undergoing a colorectal
resection developed AF within 30 days of surgery, rising
to 8.1% by 90 days. Multivariable analysis found that
increasing age (OR 1.03, 95% CI 1.01–1.06), hyperten-
sion (OR 1.73, 95% CI 1.19–2.51), congestive cardiac
failure (OR 3.04, 95% CI 1.88–4.92) and peripheral
vascular disease (OR 2.29, 95% CI 1.39–3.37) were
associated with the development of postoperative AF,
yielding an area under the curve (AUROC) of 0.733.
This study had limitations as it is likely that the
underlying population only underwent assessment for
AF when symptomatic, and a proportion may have had
asymptomatic AF. In terms of prognostic research this
equates to a PROGRESS II stage study as it identifies
factors which might be linked to outcome [4]. A PRO-
GRESS III study would test the proposed model
robustly in the target population [5].
If the incidence of postoperative AF is high in the
postresection population, a large number of patients
could potentially benefit from an accurate prognostic
model for its occurrence. The identification of high-risk
populations might allow the introduction of cost-effec-
tive screening strategies and research into mitigation
procedures. It would also better aid the consent and
counselling of patients undergoing major colorectal can-
cer surgery.
The aim of this study is to accurately define the rate
of AF within 90 days of surgery for colorectal cancer,
and to test whether we can identify those at highest risk
of developing postoperative AF.
Method
This protocol has been prepared with reference to the
SPIRIT guidelines. The study has been registered on
the clinicaltrials.gov database (NCT04037319) and is
funded by the NIHR RfPB Programme (PB-PG-1217-
20015).
The study has a prospective cohort design. It will
take place at clinical sites within the UK which offer
elective surgery for colorectal cancer.
Eligibility criteria
Patients aged 65 years or older who are undergoing elec-
tive surgery for colorectal cancer with curative intent and
who are without a diagnosis of AF are eligible. Surgery
can include laparoscopic, open or robotic approaches,
and includes right/left hemicolectomy, subtotal colec-
tomy, anterior resection and abdominoperineal excision.
Formation of stoma or anastomosis does not affect eligi-
bility. It does not include those undergoing pelvic exen-
teration, excision of locally recurrent rectal cancer,
surgery for anal cancer or those undergoing cytoreduc-
tive type procedures. Those with preexisting AF (either
persistent or paroxysmal), who have a life expectancy of
less than 12 months or who are unable to provide
informed consent will not be eligible to participate.
Additional investigations
Cardiac rhythm will be assessed using two tools. The
first is a standard 12-lead ECG. The second is a 24-h
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rhythm recording using a standard three-lead Holter
monitor for ambulatory (i.e. at home) recording of
rhythm.
Outcomes
The primary outcome is the occurrence of new-onset
AF within 90 days following colorectal cancer surgery.
AF is defined as ≥ 30 s of AF identified on a 24-h car-
diac rhythm tape or on an ECG.
Secondary outcomes include:
1 estimation of the proportion of patients with preva-
lent AF undergoing surgery for CRC;
2 description of the baseline characteristics of patients
who develop postoperative AF;
































Figure 1 Factors associated with the development of postoperative atrial fibrillation.
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4 use of data to test the performance of a predictive
model to identify the highest risk strata;
5 measurement of the quality of life in patients with
and without AF after surgery for colorectal cancer.
Participant timeline
In order to identify AF, each participant will undergo
five discrete assessments of cardiac rhythm. Prior to
recruitment a routine ECG will be reviewed for evi-
dence of AF. Providing this does not show AF, the par-
ticipant may enter into the study. He or she will
undergo a further 24-h rhythm (Holter monitor) assess-
ment prior to surgery. Preoperatively, one additional
blood test (Nt-Pro BNP) will be taken to inform the
risk model. Surgery and perioperative care will be per-
formed as normal with no deviations from usual care.
As part of routine care, any AF which develops during
surgery will be noted. Formal reassessment of rhythm
will be undertaken by ECG on the day of discharge,
and two further periods of 24-h monitoring at 30 and
90 days following surgery ( 7 days).
Sample size
We aim to recruit 720 participants undergoing elective
colorectal cancer resection. This allows for a 5% with-
drawal/dropout rate and assumes an incidence of AF of
around 15%. Withdrawals will comprise patients who
are identified as having preoperative AF on 24-h tape
following initial consent; participants who die following
surgery without a diagnosis of AF having been made
will also be excluded from analysis. With an expected
15% incidence of AF the remaining number of patients
(around n = 684 individuals) fulfils the recommenda-
tion by Collins et al. [6] that a minimum of 100 events
are needed to validate an existing prognostic model,
and also meets the recommended 10 events per covari-
ate rule for developing new prognostic models. The
sample size will also allow the postoperative incidence
of AF to be estimated within a standard error of
< 1.5%.
Recruitment
Patients will be recruited from 15 NHS sites in the UK
over an 18-month recruitment period. They will be
identified through colorectal cancer multidisciplinary
team meetings when surgery is the proposed treatment
for their colorectal cancer. Potential participants should
be approached following the clinic where surgery is dis-
cussed and screened for eligibility. Patients can be
approached by the local principal investigator (PI) or
delegated team members with the appropriate good
clinical practice (GCP) training. The patient will be
given a written information sheet to consider (see
Appendix S1) and allowed at least 24 h to consider par-
ticipation. Patients willing to take part in the study will
then provide written consent. This is anticipated to take
place at preoperative assessment appointments or other
regular clinical contacts prior to the day of surgery.
Recruitment must be completed to allow time for a 24-
h Holter recording to be analysed prior to surgery. The
patient’s GP and consultant will be informed of their
participation in the study.
A patient can withdraw from the study at any point,
without giving reasons. The data collected up to the
point of withdrawal will be retained. The date of with-
drawal will be documented in the database and the
recruitment log updated. If patients withdraw from the
study their normal routine care will continue. Partici-
pants will be withdrawn if AF is detected before the
operation.
Data collection methods
A summary of data collection points is shown in Table 2.
A pseudonymized scan of the ECG will be uploaded to
the research database. It is expected that local services will
review all their own ECGs; however, the first ECG from
each site will be reviewed centrally for monitoring pur-
poses. The remaining ECGs will undergo central assess-
ment following completion of the study.
The following data will be collected prior to opera-
tion (defined as entry into the anaesthetic room):
demographic data, including gender, age, ethnicity,
height, weight, body mass index, smoking status, and
disease characteristics, including tumour location, radi-
ology staging, evidence of metastatic spread, Dukes
classification, co-morbidities, concurrent medications
with cardiac effects, EQ-5D-5L quality of life question-
naire and blood test for N-terminal pro B-type
Table 1 Factors in the original model.
Odds ratio 95% CI
Age (years) 1.03 1.01–1.06
Male sex 1.23 0.86–1.76
Prior stroke 1.83 0.82–4.08
Congestive cardiac failure 3.04 1.88–4.92
Hypertension 1.73 1.19–2.51
Diabetes mellitus 0.73 0.46–1.16
Vascular disease 2.29 1.39–3.77
Area under the receiver-operator curve = 0.733.
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natriuretic peptide (NT-proBNP). The blood test can
be taken at any time between listing for surgery up to
the morning of the operation.
Results of blood tests for serum potassium, magne-
sium and calcium will be captured only if performed as
part of routine care. Equally, if cardiopulmonary exer-
cise testing or echocardiogram are performed preopera-
tively as routine care a pseudonymized copy of the
report will be uploaded to the database.
A 24-h recording of cardiac rhythm will be under-
taken prior to surgery to confirm the absence of AF.
This can be completed (i.e. the 24-h recording ends) at
any time prior to the patient’s operation. The results
will be analysed by local services and the pseudony-
mized scanned summary report uploaded to the
research database. If AF is reported, the patient will not
be withdrawn from the study.
The following information will be collected at opera-
tion: operative approach, operation description, anaes-
thesia modalities (i.e. inhalational general anaesthetic,
spinal/epidural anaesthesia), American Society of Anes-
thesiologists status, duration of operation, occurrence
of intra-operative AF identified by the anaesthetist. If
AF is detected during the operation, the patient is not
withdrawn from the study.
The following information will be collected at dis-
charge: ECG test with assessment for AF, occurrence of
AF prior to discharge and associated treatment and
length of hospital stay. Key complications occurring up
to the point of discharge will be identified from clinical
notes using predefined definitions. These include: in-
hospital mortality, urinary tract infection, development
of pneumonia, development of cardiac complications,
deep-vein thrombosis, delirium, surgical site infection,
fascial dehiscence, anastomotic leakage, radiological
drainage, re-operation and unplanned escalation of care.
Appendix S2 in the online Supporting Information
gives a summary of definitions.
Follow-up at 30 and 90 days includes repeated 24-h
Holter monitoring (interpreted locally) and administra-
tion of the EQ-5D-5L score. At day 90, a brief ques-
tionnaire will be administered about the use of health
services for cardiac complaints. Patients who do not
attend their 90-day follow-up visit will be ‘lost to fol-
low-up’, and should be recorded on the recruitment
log. Routine follow-up for colorectal cancer will be
undertaken as per local guidance.
Data management
Data will be collected and stored online through a
secure server running the Research Electronic Data
Capture (REDCap) web application [7]. REDCap
allows collaborators to enter and store data in a secure
system. All transmission and web storage by this system
is encrypted using ‘SSL’ and compliant with HIPAA-
Security Guidelines the United States. System users will
be allocated to a data access group for their hospital.


















ECG (if AF is detected,
the patient is not
included in the study)
x x
Consent x




EQ-5D-5L x x x
Blood tests: NT-proBNP
(K, Mg, Ca if available)
x
24 h cardiac rhythm x x x
Echo (if available) x
CPET (if available) x
Operation details X
Any surgical complications x
Health service use x
AF, atrial fibrillation; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; GP, general practitioner; NT-proBNP, N-ter-
minal pro b-type natriuretic peptide.
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This allows them to create and edit records entered by
their own team but not those from other hospitals. Col-
laborators will be required to set passwords which
include letters, numbers and special characters. Pass-
words will be changed every 30 days. The REDCap ser-
vers are encrypted and are hosted in a secure building
at the University of Sheffield, and undergo regular
back-up. The sponsor (Sheffield Teaching Hospitals
NHS Foundation Trust, STH) and University of Shef-
field are joint data controllers. The study team at the
University of Sheffield will have access to the data for
statistical analysis at the end of the study.
Data from this study will be securely retained on
University of Sheffield servers for up to 15 years after
the study has ended and will not be sent outside the
UK. Sites will be responsible for archiving the source
data, case report forms and other essential documents at
their own site for a period of up to 15 years.
Statistical methods
Analyses will be undertaken in accordance with the TRI-
POD statement [8]. The number and percentage of
patients screened, the number eligible, the number ineli-
gible due to prevalent AF and the number consenting to
study will be reported. The incidence of postoperative AF
at 30- and 90-day follow-up will be presented along with
95% CIs. The first stage will be to validate the previously
derived model for predicting 30- and 90-day AF on the
basis of routinely collected risk factors. Factors included
in the model were age, sex, cardiovascular comorbidities
and diabetes. These are shown in Table 1.
The original model will be fitted to the prospectively
collected data. We will firstly apply the original coeffi-
cients (Table 1) to the new data set and assess the
AUROC, and thereafter re-estimate coefficients for the
same covariates by logistic regression. The difference
between the two AUROCs will indicate the degree of
shrinkage (or overfitting) and thereby the stability of
the original model. Thereafter the incremental value of
the additional factors (e.g. ECG parameters, NT-
proBNP) will be assessed. If several potential candidate
covariates are identified a least absolute shrinkage and
selection operator (LASSO) analysis will be performed
to avoid overfitting. Finally, an exploratory analysis will
assess whether changes in ECG measures between base-
line and postoperative ECG can predict subsequent new
onset AF. The functional form of continuous predictors
in relation to outcome will be assessed using lowess
smoothing and fractional polynomials. The stability of
the models will be assessed using bootstrap methods
with visual calibration methods. The performance of the
competing models will be evaluated by calculating the
AUROC together with the sensitivity, specificity and
positive and negative predictive values for various cut-
off points of the risk score to assess whether individual
predictions may be made with adequate specificity with-
out compromising sensitivity. The EQ-5D-5L question-
naire will be used to derive health utility using UK
reference populations. Changes in the quality of life
index will be calculated and compared between groups
with postoperative AF and no postoperative AF, and
also between those with symptomatic AF and those
with asymptomatic AF. If a viable prognostic model is
identified, further modelling will be undertaken to
assess the cost-effectiveness of implementing a risk-
based screening programme for postsurgical AF using
these data.
Analysis population and missing data
Analyses will include all participants with the exception
of (1) patients with AF detected on preoperative investi-
gations and (2) participants who die without a diagnosis
of AF. Participants who do not complete their 30- and
90-day Holter assessments will be included in the pri-
mary analysis using incidence of AF recorded in their
clinical notes. A sensitivity analysis will exclude partici-
pants who do not complete their 90-day assessment.
EQ-5D-5L data will only be included if all items con-
tain a response.
Data monitoring
The first ECG from each site will be monitored by the
sponsor. Data monitoring will be undertaken periodi-
cally by the steering and management groups. This will
serve two purposes: (1) to identify missing data and ini-
tiate action to remedy this and (2) to identify poten-
tially outlying/erroneous data and initiate action to
remedy this. Data issues relating to either of the above
criteria will be identified and actioned by the manage-
ment group. A log of queries and outcomes will be
maintained and presented to the steering group.
The sponsor will ensure that research ethics commit-
tee approval and health research authority (HRA)
approval are in place. The study will be registered with
the local R&D office at each NHS site and it is the
responsibility of each site to ensure that recruitment
does not commence until local confirmation of capacity
and capability has been given. Each site will be responsi-
ble for setting up and maintaining an investigator site
file. Sites will all conduct the study to good clinical
practice (GCP) standards. The PIs at each site and dele-
gated team members taking part in the consent process
will be required to have GCP training.
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The study will not be monitored at individual sites;
however, a site initiation teleconference will be con-
ducted before each site opens covering the research
background, study visits, CRF completion and database
training. The sponsor will retain a site initiation visit
attendance log and delegation log from each participat-
ing site. Any protocol deviations and violations should
be reported to the sponsor’s site.
In addition, the study is overseen by a steering group
who are independent of the study. This includes an
intensivist, a colorectal surgeon, a cardiologist and an
expert in prognostic factor research.
Harms
This is an observational study; we therefore do not
anticipate any serious adverse events relating directly to
participation in this study. It is possible that patients
may experience a local inflammatory reaction to the
monitor pads. This should be recorded using the
adverse event form. Any serious unexpected serious
adverse reactions related to the study will be reported
to the chief investigator and sponsor within 24 h of
occurrence. Reports will be reviewed by the steering
group and appropriate action taken. This may range
from no action to modification of the study protocol.
Auditing
The first ECG from each site will be monitored by the
sponsor. Data monitoring will be undertaken periodi-
cally by the steering and management groups. This will
serve two purposes: (1) to identify missing data and ini-
tiate action to remedy this and (2) to identify poten-
tially outlying/erroneous data and initiate action to
remedy this. Data issues relating to either of the above
criteria will be identified and actioned by the manage-
ment group.
Ethical approval
Ethical review and approval has been conducted by East
Midlands NHS Research Ethics Committee (ref. 19/
EM/0257). HRA approval was secured prior to the
commencement of the study (IRAS ID 261310).The
study is registered on the clinicaltrials.gov website.
It is the responsibility of each participating NHS site
to ensure that recruitment does not commence until
local confirmation of capacity and capability has been
given.
Amendments to the study will be reviewed and
approved by the ethics committee and HRA and dis-
seminated to participating sites as appropriate.
Public and patient involvement
Improvement of outcomes following surgery in the
older patient has been identified by the James Lind Alli-
ance as a research priority. A focus group was con-
ducted prior to commencement of the study with
people aged 65 and older who had undergone surgery
for colorectal cancer. They confirmed the acceptability
of the additional monitoring, and the importance of the
study. All indicated they would participate if offered the
opportunity.
The study management group included a lay mem-
ber, who has had to withdraw. A replacement is being
sought, along with a lay member with experience of
AF. They will be involved in all project management
group meetings, advise on patient-facing materials and
advise the team on how to share findings with patients.
Protocol amendments
Protocol amendments will be approved by the HRA,
and communicated to all PIs and research and develop-
ment teams by a member of the project management
group.
Confidentiality
All data will be handled in accordance with GDPR
2018 principles. The database will contain pseudony-
mized study data, patients’ NHS numbers and consent
forms for monitoring purposes. Patients will be required
to provide consent for this. NHS numbers will be col-
lected for a follow-on data linkage study to look at
longer-term patient outcomes. Data will be held
securely, and will be accessible only by members of the
research team. The dataset will be limited to those data
that are necessary for each function and will not include
NHS numbers for analysis. Only the administrator is
able to access these.
Access to data
Anonymized data may be shared with appropriately
accredited researchers who have relevant questions that
do not conflict with the primary aims of the study. Data
will only be shared if appropriate ethical approvals and
data transfer agreements are in place.
Ancillary and posttrial care
Should AF be detected, the patient will be informed
and directed to an appropriate local service (cardiology
outpatients, older persons’ surgical services, or general
practitioner).
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If a participant develops AF prior to discharge from
hospital, they will be managed as per local policies. For
example, if a patient develops AF they will be contacted
by the study team upon receipt of their Holter report.
Enquiries will be made about symptoms. If the partici-
pant is unwell, they will be directed to attend their local
emergency department. If they are well, then they will
be directed to contact their GP (who will receive a copy
of the result), or will be directed to their local older
persons clinic or cardiology outpatients, depending on
local policies.
Dissemination policy
Anonymized results will be published in peer review
journals and at appropriate medical forums including
national and international conferences and NHS meet-
ings. Findings will be shared with academic health
science networks and National Institute for Health and
Care Excellence clinical exemplar repositories. Under no
circumstances will individual patients be identified.
Authorship
The study management group will be headline authors
for this study. Site (associate) PIs and up to three other
team members will be eligible for collaborative author-
ship, assuming completion of recruitment and follow-up
of participants as agreed.
Discussion
This study will be the first to screen for AF in patients
who have undergone colorectal cancer surgery. Early
detection (and treatment) of postoperative AF could
bring benefits to patients and the health system. AF is
not just a result of complications of surgery such as
anastomotic leakage: our previous work showed it could
be diagnosed weeks to months after surgery [3]. This
temporal relationship suggests that complications alone
do not drive the development of AF.
It is generally considered that interventions to pre-
vent stroke are cost-effective due to the costs of provid-
ing long-term care following a cerebrovascular event
[9]. Other screening interventions such as smartphone-
based community ECGs have also been found to be
cost-effective for stroke prevention [10]. It is clear that
investment of time and resources into performing a
potentially curative resection only for the patient to suf-
fer a stroke is undesirable. Beyond stroke, AF is associ-
ated with a worse quality of life. As cancer outcomes
improve, we look towards quality of survival and the
avoidance of late effects of cancer treatment [11]. In
this context, AF might be considered such a ‘late
effect’. With the results of this study, we may be able
to stratify those at the highest risk of developing AF.
This would allow interventions such as screening to be
delivered in a high-risk population for maximum yield.
This might prevent or delay episodes of hospitalization
for AF or cardiac failure. There is a quality of life ben-
efit associated with this. Identification of a high-risk
stratum would also provide a useful sub-population
upon which to trial prophylactic interventions. Indeed,
the inclusion of a heterogeneous population in previ-
ous prophylaxis trials might explain why the effects are
inconsistent.
The study has been designed to estimate the inci-
dence of postoperative AF in the colorectal cancer
cohort and to validate a model to stratify patients by
risk. Whilst previous work looked at all gastrointestinal
patients, the present study will be limited this to those
undergoing colorectal cancer surgery. This will provide
a relatively stable surgical insult, and in this context we
can more accurately assess the role of patient factors.
The study team have selected 24-h Holter monitors at
three points to monitor for AF. These time points were
based upon earlier work which showed that rates of
new AF plateaued at around 90 days after surgery [3].
Whilst tools such as implantable monitors are available
[12], our public and patient involvement exercise told
us that an additional invasive procedure around the time
of cancer surgery would be unwelcome. As a noninva-
sive investigation, Holter monitors were considered
acceptable. Other types of monitors would also have
cost implications, at least doubling the funding required
to deliver this study.
This study began recruiting in January 2020 and has
recruited three patients per month at open sites. Chal-
lenges have been met during set-up in relation to the
excess treatment costs related to the performance of
Holter monitors as well as the availability of testing.
The research team have purchased a limited number of
Holter monitors to aid sites in this regard. At the time
of writing, the study has been halted temporarily due to
the COVID-19 pandemic. The patient population
under study is at high risk and advised to isolate. It
would be ethically difficult to justify asking patients to
attend hospital for additional tests (Holter monitoring)
when it is not part of their cancer treatment. An exten-
sion to recruitment has been secured to allow the
remaining recruitment period to continue once pan-
demic research restrictions are lifted.
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